Wuhan Hiteck Biological Pharma Co Ltd

SHE:300683 China Drug Manufacturers - Specialty & Generic
Market Cap
$646.15 Million
CN¥4.74 Billion CNY
Market Cap Rank
#11892 Global
#2889 in China
Share Price
CN¥36.22
Change (1 day)
+5.11%
52-Week Range
CN¥19.90 - CN¥59.56
All Time High
CN¥84.19
About

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more

Wuhan Hiteck Biological Pharma Co Ltd (300683) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: -0.008x

Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has a cash flow conversion efficiency ratio of -0.008x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.49 Million) by net assets (CN¥2.24 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Wuhan Hiteck Biological Pharma Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Wuhan Hiteck Biological Pharma Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥2.41 Billion CN¥22.69 Million 0.009x +341.74%
2023-12-31 CN¥2.50 Billion CN¥5.31 Million 0.002x -90.62%
2022-12-31 CN¥2.34 Billion CN¥53.03 Million 0.023x +340.20%
2021-12-31 CN¥2.34 Billion CN¥12.09 Million 0.005x +145.17%
2020-12-31 CN¥1.72 Billion CN¥-19.70 Million -0.011x -131.90%
2019-12-31 CN¥1.76 Billion CN¥63.03 Million 0.036x -16.64%
2018-12-31 CN¥1.71 Billion CN¥73.42 Million 0.043x -15.06%
2017-12-31 CN¥1.64 Billion CN¥83.08 Million 0.051x -75.28%
2016-12-31 CN¥703.35 Million CN¥143.86 Million 0.205x -23.66%
2015-12-31 CN¥596.76 Million CN¥159.89 Million 0.268x +6.18%
2014-12-31 CN¥536.59 Million CN¥135.40 Million 0.252x -16.35%
2013-12-31 CN¥254.64 Million CN¥76.82 Million 0.302x --